FDA Clocks Extra Patent Time for Heart Drug TRYVIO
Published Date: 1/27/2026
Notice
Summary
The FDA has set the official review period for the drug TRYVIO, which helps the company extend its patent protection. This means the drug maker could get extra time to keep exclusive rights, potentially affecting when generic versions can appear. If anyone thinks the dates are wrong or wants to challenge the company’s effort during review, they have until March 30 or July 27, 2026, to speak up.
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in